SINGAPORE · MEDICAL DEVICES

Singapore HSA Change Notification: GN-21 R7 Categories and Timelines

A European manufacturer holds a Singapore registration for a group of Class C infusion consumables. This year it extended shelf life from 12 to 24 months, added two models within the existing size range, and switched the tubing from PVC to silicone. The Singapore distributor asked one question: can next month’s shipment carry the new labels? The three changes follow three different routes, and only one can be implemented on submission.

In Singapore the question is not whether to notify HSA but which GN-21 category the change falls into: supplying a device before approval of a change that needs approval is unlawful supply, and sitting on a change that only needs notification is a breach as well.

Which changes cannot be filed as a change notification at all?

Start by removing what is not on the menu. GN-21 Section 2 states that the following fall outside change notification and require a new product registration: a change to the intended purpose of a registered medical device or IVD; a change to its risk classification; adding models that do not meet the GN-12 grouping criteria; changing the medicinal substance in an ancillary-role medicinal product; and adding devices with different proprietary names, unless GN-12 allows them in the same listing. For machine-learning-enabled devices, Flowchart 2.5 sends a change to new premarket submission where a new input is needed for a new output or a workflow change alters the risk class.(Source: HSA GN-21 R7 Guidance on Change Notification for Registered Medical Devices, 2026-08-01, §2 and Flowchart 2.5)

For commercial teams the point is budgetary: an indication extension or a sister product under a different brand, however “minor” the product owner calls it, is a full registration in Singapore. HSA’s web page lists the same five exclusions.(Source: HSA Change Notification, 2026-10-21)

How do the four categories work, and which ones can be implemented on acknowledgement?

GN-21 assigns each change to a category through the Section 3 flowcharts, and the category decides whether prior approval is needed. Technical changes (Class C and D) affect safety, quality or performance, such as a shelf-life extension. Review changes are a closed list for Class B: changes to indications, addition of models, revised warnings or contraindications, a modified method of use. Administrative changes cover registration documents and SMDR listing particulars for Class B, C and D. Notification changes may be implemented once HSA’s acknowledgement e-mail arrives after SHARE submission; examples are deletion of models (6B), certain labelling changes (5D/5E) and submission of UDI data (6E).(Source: HSA GN-21 R7, 2026-08-01, §2 Table 1, §3 Flowchart 6, Annex 3)

Class A devices sit in the Class A Medical Device Database rather than the SMDR. GN-21 Section 2.1 states that change notification should not be submitted for Class A devices; dealer licensing and post-market duties still apply, with the details in GN-22.(Source: HSA GN-21 R7, 2026-08-01, §2.1)

What changed in R7, and why do 6Aii/6Aiii deserve attention?

R6 (effective 14 July 2025) expanded the list of changes needing no change notification, added Flowchart 2.5 for machine-learning-enabled devices, introduced change type 6E for UDI data, removed the marketing-history requirement for 6Ai and confirmed that Class A devices need no change notification.(Source: HSA Regulatory Updates: Updates to GN-21, 2025-07-04)

R7 (document version 6.1, effective 1 August 2026) concentrates on the Administrative category. Section 2 carries an R7 marker stating that Administrative changes, including SMDR listing additions under Flowchart 6A items 6Aii/6Aiii (for example new models within an existing size range or a change in pack count), require HSA’s approval prior to implementation. Annex 2 also now caps active change notifications at two per listing.(Source: HSA GN-21 R7, 2026-08-01, revision history, §2, Annex 2)

One inconsistency should be flagged. HSA’s change notification web page, updated 21 October 2026, still lists administrative changes under 6Aii/6Aiii alongside Notification changes as implementable on receipt of the acknowledgement e-mail. Where guidance and web page differ, the prudent approach is to plan on the stricter reading in the guidance and to treat HSA’s actual response in SHARE, whether acknowledgement or approval letter, as the trigger for implementation.(Source: HSA Change Notification, 2026-10-21)

What if several changes happen together, or a change arises from an adverse event or FSCA?

When one application contains several changes, each is categorised separately and the whole application is charged and assessed at the most stringent category; non-identical administrative and technical changes must be filed as separate applications. Notification changes may be bundled, but only within six months of first implementation anywhere in the world. A Notification change that HSA finds to have been wrongly categorised is rejected, and further supply is prohibited.(Source: HSA GN-21 R7, 2026-08-01, §2 and §4 Note 1)

Changes driven by a reportable adverse event or a field safety corrective action (FSCA) have their own rule: whatever the flowchart category, prior approval is required unless HSA advises otherwise in writing. Such Notification-category changes may proceed only after the AE or FSCA has been reported to HSA, cannot be bundled, and may not qualify for concurrent supply of the unchanged version.(Source: HSA GN-21 R7, 2026-08-01, §2.2 and §4.2)

What do fees, turnaround and the SHARE system mean for planning?

Fees are set on HSA’s fee page: S$560 for Administrative changes in every class and for Class B Review changes, S$1,890 for Class C Technical and S$3,120 for Class D Technical changes, with no fee for Notification changes. Target turnaround is 30, 45, 75 and 90 working days respectively, excluding the applicant’s stop-clock time. Fees are non-refundable, including on withdrawal or rejection.(Source: HSA Medical Device Fees and Turnaround Time, 2026-03-26)

Since 14 July 2025 all medical device applications are submitted in SHARE (Singapore Health Product Access and Regulatory E-System); MEDICS e-services are being decommissioned and redirect to SHARE. Application status is shown in the SHARE inbox with e-mail notifications.(Source: HSA Regulatory Updates: Progressive decommissioning of MEDICS e-services, 2025-07-04)

For scheduling, a Technical change needs more than a quarter in the plan, and Singapore should be a separate line in the product owner’s global changeover calendar. The two-active-applications cap means several Technical changes cannot be compressed by parallel filing, so sequencing has to be decided at the start. A hypothetical illustration: a shelf-life extension (Technical, 90 working days) and a pack-count change (Administrative, 30 working days) filed separately for Q1 2027 means the new pack can ship under the old shelf-life labelling first, while the extended shelf life appears on labels only after approval.

How does change notification relate to change of registrant?

They are different procedures. A change in the product owner’s name or address is change type 6D, an Administrative change for all classes, and the application must include a phase-out timeline for old and new stock. Replacing the Singapore registrant is a separate application under GN-24, at S$880 with a target turnaround of 40 working days.(Source: HSA Medical Device Fees, 2026-03-26; HSA GN-21 R7, 2026-08-01, Flowchart 6 and §4.2)

In MediPass’s experience, complete change-of-registrant applications are usually approved within about two weeks, well inside the 40-working-day target. One practical rule still applies: a change notification pending during a registrant change creates two files with different applicants, so it is usually better to complete the registrant change first and let the new registrant file subsequent changes.